Percutaneous Coronary Intervention (PCI) Clinical Trials

Clinical trials related to Percutaneous Coronary Intervention (PCI) Procedure

The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

DAN-RELEASE is a national, randomized, registry-based trial including 7,000 participants in Denmark. The trial aims to determine whether discontinuation of long-term aspirin therapy is non-inferior to continued aspirin therapy in older adults with stable ischemic heart disease. Long-term aspirin therapy is recommended for patients with established ischemic heart disease. However, among clinically stable patients years after percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or myocardial infarction (MI), the evidence supporting lifelong aspirin therapy is limited. At the same time, the risk of serious bleeding increases with age. DAN-RELEASE will therefore compare aspirin discontinuation with continued aspirin therapy in adults aged 65 years or older with stable ischemic heart disease who have remained free from ischemic events for at least two years. The trial will assess whether discontinuing aspirin is non-inferior to continued treatment with respect to cardiovascular and bleeding outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:

• Age ≥65 years at randomization

• Ischemic heart disease (IHD) with index event (myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG)) \>2 years previously

• Since index event free from ischemic cardiovascular events (MI, ischemic stroke, or transitory ischemic attack) or any coronary revascularization procedure (PCI/CABG)

• Currently treated with low dose aspirin (≤150 mg daily)

Locations
Other Locations
Denmark
Bispebjerg Frederiksberg Hospital
RECRUITING
Copenhagen
Odense Universitetshospital
RECRUITING
Odense
Contact Information
Primary
Axel Diederichsen, Professor
Axel.Diederichsen@rsyd.dk
+4540191227
Backup
Eva Prescott, Professor
eva.irene.bossano.prescott@regionh.dk
+4540262134
Time Frame
Start Date: 2026-09-30
Estimated Completion Date: 2029-10
Participants
Target number of participants: 7000
Treatments
Active_comparator: Continuation of Aspirin
Participants randomized to this arm will continue their current long-term low-dose aspirin therapy.
Active_comparator: Discontinuation of Aspirin
Participants randomized to this arm will discontinue their current long-term low-dose aspirin therapy.
Sponsors
Leads: Odense University Hospital
Collaborators: University Hospital Bispebjerg and Frederiksberg

This content was sourced from clinicaltrials.gov

Similar Clinical Trials